Phase 1
N=16
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
COVID 19
Bottom Line
View on ClinicalTrials.gov: NCT04343092 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcome: Primary: Number of Cured Patients — 16 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Ivermectin (IVM) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Baghdad
- Primary completion
- May 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Cured Patients |
16 | — |
| SECONDARY Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group |
7.62 | 0.05 |
Summary
Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)
Eligibility Criteria
Inclusion Criteria
-1. Patients with age above 18 years and any gender with definite Dx of covid19 and pneumonia in the ward according to the clinical, laboratory, and imaging criteria.
- Understands and agrees to comply with planned study procedures.
Exclusion Criteria
- Patients with hypersensitivity or severe adverse effects to Ivermectin
- Renal impairment
- Hepatic impairment.
- Pregnancy or a desire to become pregnant (drug considered pregnancy category c)
- Breast feeding.
- Patient with covid 19 positive and mild no pneumonia
- Children under the age of five or those who weigh less than 15 kilograms
Data sourced from ClinicalTrials.gov (NCT04343092). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.